158 related articles for article (PubMed ID: 6518137)
1. Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy.
Boccadoro M; Gavarotti P; Fossati G; Pileri A; Marmont F; Neretto G; Gallamini A; Volta C; Tribalto M; Testa MG
Br J Haematol; 1984 Dec; 58(4):689-96. PubMed ID: 6518137
[TBL] [Abstract][Full Text] [Related]
2. Lack of correlation between plasma cell thymidine labelling index and serum beta-2-microglobulin in monoclonal gammopathies.
Boccadoro M; Durie BG; Frutiger Y; Gavarotti P; Redoglia V; Massaia M; D'Alberto M; Marmont F; Gallamini A; Tribalto M
Acta Haematol; 1987; 78(4):239-42. PubMed ID: 3122489
[TBL] [Abstract][Full Text] [Related]
3. A contribution to examination of propidium iodide and annexin V plasma cells indices in multiple myeloma.
Scudla V; Ordeltova M; Bacovsky J; Vytrasova M; Sumna E; Martinek A; Horak P
Neoplasma; 2003; 50(5):363-71. PubMed ID: 14628090
[TBL] [Abstract][Full Text] [Related]
4. Determination of the growth fraction in monoclonal gammopathy with the monoclonal antibody Ki-67.
Lokhorst HM; Boom SE; Terpstra W; Roholl P; Gerdes J; Bast BJ
Br J Haematol; 1988 Aug; 69(4):477-81. PubMed ID: 3044442
[TBL] [Abstract][Full Text] [Related]
5. Plasma cell acid phosphatase activity as prognostic factor in multiple myeloma: relationship to the thymidine-labeling index.
Boccadoro M; Gallamini A; Fruttero A; Gavarotti P; Redoglia V; Buffa F; Ruá S; Pileri A
J Clin Oncol; 1985 Nov; 3(11):1503-7. PubMed ID: 4056842
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibody Ki-67 as a marker of proliferative activity in monoclonal gammopathies.
Girino M; Riccardi A; Luoni R; Ucci G; Cuomo A
Acta Haematol; 1991; 85(1):26-30. PubMed ID: 2011926
[TBL] [Abstract][Full Text] [Related]
7. Clinical, morphological, and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma.
Greipp PR; Kyle RA
Blood; 1983 Jul; 62(1):166-71. PubMed ID: 6407546
[TBL] [Abstract][Full Text] [Related]
8. Serum thymidine kinase in monoclonal gammopathies. A prospective study. The Cooperative Group for Study and Treatment of Multiple Myeloma.
Luoni R; Ucci G; Riccardi A; Gobbi P; Avato FM; Vignale C; Ascari E
Cancer; 1992 Mar; 69(6):1368-72. PubMed ID: 1540874
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
[TBL] [Abstract][Full Text] [Related]
10. Ploidy and proliferative characteristics in monoclonal gammopathies.
Latreille J; Barlogie B; Johnston D; Drewinko B; Alexanian R
Blood; 1982 Jan; 59(1):43-51. PubMed ID: 6172171
[TBL] [Abstract][Full Text] [Related]
11. Is multidrug resistance (P-glycoprotein) an intrinsic characteristic of plasma cells in patients with monoclonal gammopathy of undetermined significance, plasmacytoma, multiple myeloma and amyloidosis?
Mongkonsritragoon W; Kimlinger T; Ahmann G; Greipp PR
Leuk Lymphoma; 1998 May; 29(5-6):577-84. PubMed ID: 9643571
[TBL] [Abstract][Full Text] [Related]
12. The diagnostic value of SE MRI and DWI of the spine in patients with monoclonal gammopathy of undetermined significance, smouldering myeloma and multiple myeloma.
Dutoit JC; Vanderkerken MA; Anthonissen J; Dochy F; Verstraete KL
Eur Radiol; 2014 Nov; 24(11):2754-65. PubMed ID: 25106487
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic and prognostic value of the MB2 monoclonal antibody in paraffin-embedded bone marrow sections of patients with multiple myeloma and monoclonal gammopathy of undetermined significance.
Dehou MF; Schots R; Lacor P; Arras N; Verhavert P; Klöppel G; van Camp B
Am J Clin Pathol; 1990 Sep; 94(3):287-91. PubMed ID: 1697732
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow percentage of plasma cells in the staging of monoclonal gammopathies.
Vercelli D; Di Guglielmo R; Guidi G; Scolari L; Buricchi L; Cozzolino F
Nouv Rev Fr Hematol (1978); 1980; 22(2):139-45. PubMed ID: 7422542
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
Hillengass J; Moehler T; Hundemer M
Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
[TBL] [Abstract][Full Text] [Related]
16. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.
Kloth JK; Hillengass J; Listl K; Kilk K; Hielscher T; Landgren O; Delorme S; Goldschmidt H; Kauczor HU; Weber MA
Int J Cancer; 2014 Nov; 135(10):2380-6. PubMed ID: 24706394
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
[TBL] [Abstract][Full Text] [Related]
18. DNA aneuploidy, increased proliferation and nuclear area of plasma cells in monoclonal gammopathy of undetermined significance and multiple myeloma.
Leo E; Kropff M; Lindemann A; Steinfurth G; Esselborn H; Rossner R; Adler CP; Böcking A
Anal Quant Cytol Histol; 1995 Apr; 17(2):113-20. PubMed ID: 7612131
[TBL] [Abstract][Full Text] [Related]
19. Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells.
Sezer O; Heider U; Zavrski I; Possinger K
Haematologica; 2001 Aug; 86(8):837-43. PubMed ID: 11522540
[TBL] [Abstract][Full Text] [Related]
20. Plasma cell proliferation in monoclonal gammopathies: measurement using BU-1 antibody in flow cytometry and microscopy: comparison with serum thymidine kinase.
Schambeck CM; Wick M; Bartl R; Lamerz R; Fateh-Moghadam A
J Clin Pathol; 1995 May; 48(5):477-81. PubMed ID: 7629298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]